Remedy Plan Therapeutics Begins Phase 1 Trial Dosing of RPT1G, a Novel NAMPT Inhibitor

GAITHERSBURG, Md., Dec. 18, 2024 – Remedy Plan Therapeutics, a clinical-stage pharmaceutical company, has embarked on a significant milestone with the initiation of a Phase 1 clinical trial focusing on RPT1G, its pioneering hyperbolic NAMPT inhibitor. This new class of drug aims to selectively target cells with elevated NAMPT levels, which are often present in various types of cancer as well as autoimmune and metabolic disorders. Importantly, RPT1G is engineered to minimize toxicity to healthy cells, thus safeguarding normal cellular functions.

The clinical trial is structured as a randomized, double-blind, placebo-controlled study and involves adult healthy volunteers in Australia. This study, registered under NCT06667765, is designed to assess the safety profile and pharmacokinetic characteristics of RPT1G, while also investigating its pharmacodynamic effects. Results from this initial phase are anticipated in the first half of 2025, laying the groundwork for advancing the company's oncology program. Remedy Plan Therapeutics plans to launch subsequent trials in the second half of 2025, targeting acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

Dr. Greg Crimmins, the founder and CEO of Remedy Plan Therapeutics, expressed enthusiasm about the trial's commencement. He highlighted that RPT1G is not only the first hyperbolic NAMPT inhibitor but also the first NAMPT inhibitor to be trialed in healthy human subjects. This step underscores the extensive preclinical research that has demonstrated the promising safety profile of these inhibitors. Dr. Crimmins emphasized that the findings from this trial would be instrumental in launching trials with cancer patients at a dose that could offer substantial therapeutic benefits.

RPT1G represents a novel class of small molecule NAMPT inhibitors with a design that prioritizes preserving the biological integrity of healthy cells. Compared to previous complete NAMPT inhibitors, RPT1G has shown a favorable efficacy and tolerability profile in preclinical models. This supports its potential use in treating both hematological malignancies and solid tumors. Furthermore, preclinical studies have revealed that RPT1G not only works effectively on its own but also enhances the effects of current standard treatments. It has been shown to overcome resistance in cancer cells to drugs like venetoclax, suggesting improved therapeutic outcomes for leukemia patients. The scientific validation of NAMPT's role in autoimmune and metabolic diseases further positions RPT1G analogues as promising candidates for treating these conditions.

Remedy Plan Therapeutics, a privately-held pharmaceutical company, is revolutionizing the NAMPT inhibition landscape with its innovative research and development efforts. With RPT1G leading its portfolio, the company is poised to make significant contributions to the treatment of cancer, autoimmune, and metabolic diseases. The initiation of the Phase 1 clinical trial in November 2024 marks a critical step in this journey, as the company continues to explore the vast potential of its therapeutic assets.